Technical Data
BARD1 (BRCA1 Associated Ring Domain 1)
BARD1 interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, BARD1 shares homology with the 2 most conserved regions of BRCA1: the N-terminal ring motif and the C-terminal BRCT domain. The ring motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. The BARD1 protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interation is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. BARD1 may be the target of oncogenic mutations in breast or ovarian cancer.

Suitable for use in Dot Blot, Western Blot and Immunoprecipitation. Other applications have not been tested.

Recommended Dilution:
Western Blot: 0.2-2ug/ml.
Immunoprecipitation: 100-500ug/sample
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage, aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
MabIgG18C29Affinity Purified
50ug4C (-20C Glycerol)Blue IceHumanMouse
Synthetic peptide corresponding to aa50-200 from the internal region of human BARD1.
Purified by Protein G affinity chromatography.
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.05% sodium azide, before the addition of glycerol to 40%.
Recognizes human BARD1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.